{
  "analyst_run_id": "RUN-20260715-600276-20260715060833015364-dca54466",
  "decision": {
    "chase_limit": 58.0,
    "decision": "WAIT",
    "entry_max": 57.5,
    "entry_min": 56.0,
    "invalid_conditions": [
      "次日开盘半小时内股价放量跌破55元，或成交量低于30亿元；创新药指数日内跌幅超2%；龙虎榜显示主力大幅净卖出。",
      "普通股票推荐分数低于80"
    ],
    "main_theme": "创新药",
    "position_limit": 0.0,
    "raw": {
      "chase_limit": 58.0,
      "decision": "BUY_CONDITIONAL",
      "entry_max": 57.5,
      "entry_min": 56.0,
      "evidence_ids": [
        "EVD-e002fa33758068be",
        "EVD-f99a9fd1ae0cd4a9",
        "EVD-7e82f8af6a933fd9",
        "EVD-501bc402d114fd4f",
        "EVD-6329bc49d47c8900",
        "EVD-67db64ca05505bb3",
        "EVD-7a80095771a1ed5e",
        "EVD-7c81d9a8a47a9018"
      ],
      "invalid_conditions": "次日开盘半小时内股价放量跌破55元，或成交量低于30亿元；创新药指数日内跌幅超2%；龙虎榜显示主力大幅净卖出。",
      "main_theme": "创新药",
      "position_limit": 0.2,
      "risk_notes": "板块情绪可能快速退潮；当前估值偏高，若业绩不及预期有戴维斯双杀风险；经营现金流低于净利润，利润质量待改善。",
      "score": 50.36,
      "setup": "LOW_VOLUME_BREAKOUT",
      "stock_name": "恒瑞医药",
      "stop_loss": 52.0,
      "summary": "恒瑞医药基本面扎实，创新药主线处于发酵期，板块情绪高涨，且无解禁压力，但技术面呈低量突破，政策催化缺失，龙虎榜数据待出，故有条件买入：回调至56-57.5元区间可轻仓介入，止损设于52元，目标62/68元。",
      "target_1": 62.0,
      "target_2": 68.0,
      "ticker": "600276"
    },
    "risk_notes": [
      "板块情绪可能快速退潮；当前估值偏高，若业绩不及预期有戴维斯双杀风险；经营现金流低于净利润，利润质量待改善。"
    ],
    "score": 50.36,
    "setup": "LOW_VOLUME_BREAKOUT",
    "stock_name": "恒瑞医药",
    "stop_loss": 52.0,
    "summary": "恒瑞医药基本面扎实，创新药主线处于发酵期，板块情绪高涨，且无解禁压力，但技术面呈低量突破，政策催化缺失，龙虎榜数据待出，故有条件买入：回调至56-57.5元区间可轻仓介入，止损设于52元，目标62/68元。",
    "target_1": 62.0,
    "target_2": 68.0,
    "ticker": "600276"
  },
  "report_ids": [
    "REPORT-20260715060851205558-2289231a5959",
    "REPORT-20260715060915068949-5a4259d22fdf",
    "REPORT-20260715060931293954-29877cb1be82",
    "REPORT-20260715060952405378-876b9acbe274",
    "REPORT-20260715060958766543-b6c28f5b24e7",
    "REPORT-20260715061008570347-a89ff3e63a5c",
    "REPORT-20260715061017522430-fc5ca92b35a0",
    "REPORT-20260715061042698368-3b14f91a26d6",
    "REPORT-20260715061100595596-a0e8f9a597cc",
    "REPORT-20260715061148816240-82f108d3829f",
    "REPORT-20260715061202784543-254ab7d9baec"
  ],
  "risk": {
    "evidence_ids": [
      "EVD-e002fa33758068be",
      "EVD-f99a9fd1ae0cd4a9",
      "EVD-7e82f8af6a933fd9",
      "EVD-501bc402d114fd4f",
      "EVD-7a80095771a1ed5e",
      "EVD-7c81d9a8a47a9018",
      "EVD-6329bc49d47c8900"
    ],
    "risk_penalty": 5.0,
    "summary": "恒瑞医药短期受创新药主题驱动放量上涨，但技术面呈低量突破形态且换手率一般，持续上行需观察量能配合；情绪面主线发酵但炸板率偏高，市场整体偏弱；政策面缺乏催化，若后续无政策跟进主题可能降温；基本面稳健但经营现金流低于净利润，存在利润质量隐忧；龙虎榜数据缺失无法评估主力资金意图；一致看多研报可能过度乐观。综合认为风险中等，建议保持观察。",
    "veto": []
  }
}